CD19 and hepatocellular carcinoma: On the other hand, the percentage of CD19+CD24intCD38int naïve mature B cells (from CD19+ B cells) was elevated in the CHC-HCC patients in comparison with both the control (mean, 48.4 ± 2 vs. 42.5 ± 2, p = 0.07) and the CHC-N group (mean, 48.4 ± 2 vs. 41.4 ± 2, p = 0.01).